Detalhe da pesquisa
1.
N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations.
Mutagenesis
; 39(2): 96-118, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38183622
2.
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Nature
; 492(7427): 108-12, 2012 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23051747
3.
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Nat Cancer
; 2(10): 1002-1017, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34790902
4.
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissues.
Sci Rep
; 10(1): 22155, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335114
5.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
6.
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Oncogenesis
; 7(4): 35, 2018 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674704
7.
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Cancer Cell
; 28(1): 57-69, 2015 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26175415
8.
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
Oncotarget
; 4(12): 2419-29, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24293458
9.
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
PLoS One
; 8(8): e72967, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24009722
10.
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Cancer Cell
; 23(5): 677-92, 2013 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23680150